Related Experiment Videos
[Combination chemotherapy for bronchogenic carcinoma based on cell type].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1986
Summary
Combination chemotherapy regimens, including CAP, PP, and CAV, were evaluated in 123 lung cancer patients. CAV showed the highest response rate, particularly in small cell carcinoma, where responders had significantly improved survival.
Area of Science:
- Oncology
- Pharmacology
Context:
- Bronchogenic carcinoma treatment involves diverse chemotherapy regimens.
- Patient stratification based on cell type is crucial for effective treatment.
Purpose:
- To evaluate the efficacy and safety of different combination chemotherapy regimens (CAP, PP, CAV) in patients with bronchogenic carcinoma.
- To compare response rates and survival outcomes across treatment groups and patient subgroups.
Summary:
- 123 patients with lung cancer received CAP (adenocarcinoma, large cell), PP (squamous cell), or CAV (small cell) chemotherapy every 4 weeks.
- Response rates were 18.3% (CAP), 20.7% (PP), and 60% (CAV). Median survival times were 12.5 (CAP), 8.5 (PP), and 9.5 months (CAV).
- Responders in small cell carcinoma showed significantly better survival. Platinum-based regimens caused severe nausea/vomiting but no renal failure. Myelosuppression was mild to moderate.
Impact:
- The study highlights the differential efficacy of chemotherapy regimens based on lung cancer cell type.
- CAV regimen demonstrates superior response rates in small cell carcinoma, suggesting tailored treatment approaches.
- Understanding treatment responses and survival in relation to performance status (PS) can guide clinical decision-making.